vs
FTI CONSULTING, INC（FCN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
FTI CONSULTING, INC的季度营收约是Revvity的1.3倍（$990.7M vs $772.1M），Revvity净利率更高（12.7% vs 5.5%，领先7.2%），FTI CONSULTING, INC同比增速更快（10.7% vs 5.9%），FTI CONSULTING, INC自由现金流更多（$351.4M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 3.3%）
FTI咨询成立于1982年，总部位于美国华盛顿特区，是全球顶尖的金融咨询服务商之一。公司核心业务涵盖企业融资与重组、经济咨询、法务与诉讼咨询、战略传播、科技及战略咨询等领域，在31个国家拥有逾7700名员工。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FCN vs RVTY — 直观对比
营收规模更大
FCN
是对方的1.3倍
$772.1M
营收增速更快
FCN
高出4.9%
5.9%
净利率更高
RVTY
高出7.2%
5.5%
自由现金流更多
FCN
多$189.6M
$161.8M
两年增速更快
RVTY
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $990.7M | $772.1M |
| 净利润 | $54.5M | $98.4M |
| 毛利率 | 31.1% | — |
| 营业利润率 | 9.4% | 14.5% |
| 净利率 | 5.5% | 12.7% |
| 营收同比 | 10.7% | 5.9% |
| 净利润同比 | 9.7% | 3.9% |
| 每股收益（稀释后） | $1.77 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCNRVTY
| Q4 25 | $990.7M | $772.1M | ||
| Q3 25 | $956.2M | $698.9M | ||
| Q2 25 | $943.7M | $720.3M | ||
| Q1 25 | $898.3M | $664.8M | ||
| Q4 24 | $894.9M | $729.4M | ||
| Q3 24 | $926.0M | $684.0M | ||
| Q2 24 | $949.2M | $691.7M | ||
| Q1 24 | $928.6M | $649.9M |
净利润FCNRVTY
| Q4 25 | $54.5M | $98.4M | ||
| Q3 25 | $82.8M | $46.7M | ||
| Q2 25 | $71.7M | $53.9M | ||
| Q1 25 | $61.8M | $42.2M | ||
| Q4 24 | $49.7M | $94.6M | ||
| Q3 24 | $66.5M | $94.4M | ||
| Q2 24 | $83.9M | $55.4M | ||
| Q1 24 | $80.0M | $26.0M |
毛利率FCNRVTY
| Q4 25 | 31.1% | — | ||
| Q3 25 | 33.3% | 53.6% | ||
| Q2 25 | 32.1% | 54.5% | ||
| Q1 25 | 32.2% | 56.5% | ||
| Q4 24 | 30.2% | — | ||
| Q3 24 | 32.2% | 56.3% | ||
| Q2 24 | 32.8% | 55.7% | ||
| Q1 24 | 32.6% | 54.6% |
营业利润率FCNRVTY
| Q4 25 | 9.4% | 14.5% | ||
| Q3 25 | 12.3% | 11.7% | ||
| Q2 25 | 10.5% | 12.6% | ||
| Q1 25 | 8.8% | 10.9% | ||
| Q4 24 | 5.9% | 16.3% | ||
| Q3 24 | 9.8% | 14.3% | ||
| Q2 24 | 11.0% | 12.4% | ||
| Q1 24 | 10.7% | 6.8% |
净利率FCNRVTY
| Q4 25 | 5.5% | 12.7% | ||
| Q3 25 | 8.7% | 6.7% | ||
| Q2 25 | 7.6% | 7.5% | ||
| Q1 25 | 6.9% | 6.4% | ||
| Q4 24 | 5.6% | 13.0% | ||
| Q3 24 | 7.2% | 13.8% | ||
| Q2 24 | 8.8% | 8.0% | ||
| Q1 24 | 8.6% | 4.0% |
每股收益（稀释后）FCNRVTY
| Q4 25 | $1.77 | $0.86 | ||
| Q3 25 | $2.60 | $0.40 | ||
| Q2 25 | $2.13 | $0.46 | ||
| Q1 25 | $1.74 | $0.35 | ||
| Q4 24 | $1.39 | $0.77 | ||
| Q3 24 | $1.85 | $0.77 | ||
| Q2 24 | $2.34 | $0.45 | ||
| Q1 24 | $2.23 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $265.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $7.3B |
| 总资产 | $3.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FCNRVTY
| Q4 25 | $265.1M | $919.9M | ||
| Q3 25 | $146.0M | $931.4M | ||
| Q2 25 | $152.8M | $991.8M | ||
| Q1 25 | $151.1M | $1.1B | ||
| Q4 24 | $660.5M | $1.2B | ||
| Q3 24 | $386.3M | $1.2B | ||
| Q2 24 | $226.4M | $2.0B | ||
| Q1 24 | $244.0M | $1.7B |
总债务FCNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $60.0M | — | ||
| Q1 24 | $205.0M | — |
股东权益FCNRVTY
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.1B | $7.9B | ||
| Q1 24 | $2.1B | $7.8B |
总资产FCNRVTY
| Q4 25 | $3.5B | $12.2B | ||
| Q3 25 | $3.5B | $12.1B | ||
| Q2 25 | $3.5B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.6B | $12.4B | ||
| Q3 24 | $3.5B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.3B | $13.4B |
负债/权益比FCNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $359.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $351.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 35.5% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 6.60× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $93.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FCNRVTY
| Q4 25 | $359.8M | $182.0M | ||
| Q3 25 | $201.9M | $138.5M | ||
| Q2 25 | $55.7M | $134.3M | ||
| Q1 25 | $-465.2M | $128.2M | ||
| Q4 24 | $315.3M | $174.2M | ||
| Q3 24 | $219.4M | $147.9M | ||
| Q2 24 | $135.2M | $158.6M | ||
| Q1 24 | $-274.8M | $147.6M |
自由现金流FCNRVTY
| Q4 25 | $351.4M | $161.8M | ||
| Q3 25 | $187.0M | $120.0M | ||
| Q2 25 | $38.3M | $115.5M | ||
| Q1 25 | $-483.0M | $112.2M | ||
| Q4 24 | $301.6M | $149.8M | ||
| Q3 24 | $212.3M | $125.6M | ||
| Q2 24 | $125.2M | $136.6M | ||
| Q1 24 | $-279.5M | $129.7M |
自由现金流率FCNRVTY
| Q4 25 | 35.5% | 21.0% | ||
| Q3 25 | 19.6% | 17.2% | ||
| Q2 25 | 4.1% | 16.0% | ||
| Q1 25 | -53.8% | 16.9% | ||
| Q4 24 | 33.7% | 20.5% | ||
| Q3 24 | 22.9% | 18.4% | ||
| Q2 24 | 13.2% | 19.7% | ||
| Q1 24 | -30.1% | 20.0% |
资本支出强度FCNRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 1.5% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 1.1% | 3.2% | ||
| Q1 24 | 0.5% | 2.7% |
现金转化率FCNRVTY
| Q4 25 | 6.60× | 1.85× | ||
| Q3 25 | 2.44× | 2.97× | ||
| Q2 25 | 0.78× | 2.49× | ||
| Q1 25 | -7.52× | 3.03× | ||
| Q4 24 | 6.34× | 1.84× | ||
| Q3 24 | 3.30× | 1.57× | ||
| Q2 24 | 1.61× | 2.87× | ||
| Q1 24 | -3.44× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCN
| Corporate Finance Segment | $423.2M | 43% |
| Forensic And Litigation Consulting | $192.9M | 19% |
| Economic Consulting | $176.2M | 18% |
| Strategic Communications | $99.4M | 10% |
| Other | $99.0M | 10% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
